Other Optic Nerve Maladies in Cancer Patients

  • Jade S. Schiffman
  • Anitha Raghunath
  • Rosa Ana Tang
Chapter
Part of the M.D. Anderson Solid Tumor Oncology Series book series (MDA, volume 6)

Abstract

Many optic neuropathies in cancer patients are related to the direct effect of cancer on the optic nerve (e.g., orbital and parasellar skull base compressive lesions or infiltration of the optic nerve with leptomeningeal disease). However, a number of optic neuropathies occur unrelated to those mechanisms. Other mechanisms of optic neuropathy in cancer patients include those caused by raised intracranial pressure (ICP), nutritional deficiencies, drugs, and radiation injury. Optic neuropathy related to elevated ICP does not initially affect vision; therefore, early recognition of the underlying problem is important for visual preservation. In patients with nutritional or drug-related optic neuropathy, symptoms and signs usually present simultaneously and bilaterally with visual loss that is progressive and painless; color vision is affected early on, but pupil examination may remain normal. The nutritional deficiencies may present slowly and symmetrically, and potential deficiencies include vitamins B12, folate, and thiamine B1. Radiation-related optic neuropathy often manifests within about 18 months after radiotherapy and usually after cumulative radiation doses greater than 50 Gy or single doses greater than 10 Gy. Patients often do not have optic disc swelling, and they develop progressive visual loss over weeks to months, with bilateral sequential loss being more common; the end result is vision of 20/200 or worse. Rarely, paraneoplastic syndrome can result in an optic neuropathy.

Keywords

Retina Neuropathy Methotrexate Tamoxifen Meningitis 

References

  1. 1.
    Foroozan R. Ocular complications of sigmoid sinus thrombosis from L-asparaginase. J Pediatr Ophthalmol Strabismus 2005;42(2):117–9.PubMedGoogle Scholar
  2. 2.
    Schroeter T, Lanvers C, Herding H, Suttorp M. Pseudotumor cerebri induced by all-trans-retinoic acid in a child treated for acute promyelocytic leukemia. Med Pediatr Oncol 2000;34(4):284–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Chan JW. Optic Nerve Disorders: Diagnosis and Management, first edition. New York, NY: Springer, 2007.Google Scholar
  4. 4.
    Kumar N. Neurologic presentations of nutritional deficiencies. Neurol Clin 2010;28(1):107–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 1991;70(4):229–45.Google Scholar
  6. 6.
    Puntambekar P, Basha MM, Zak IT, Madhavan R. Rare sensory and autonomic disturbances associated with vitamin B12 deficiency. J Neurol Sci 2009;287(1–2):285–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Golnik KC, Schaible ER. Folate-responsive optic neuropathy. J Neuroophthalmol 1994;14(3):163–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Hsu CT, Miller NR, Wray ML. Optic neuropathy from folic acid deficiency without alcohol abuse. Ophthalmologica 2002;216(1):65–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Adamolekun B. Thiamine deficiency and the etiology of tropical ataxic neuropathy. Int Health 2010;2(1):17–21.CrossRefGoogle Scholar
  10. 10.
    Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 20076(5):442–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Sadun AA, Wang MY. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year. J Neuroophthalmol 2008;28(4):265–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004;111(7):1275–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Friedman DI. Pseudotumor cerebri. Neurol Clin 2004;22(1):99–131, vi.PubMedCrossRefGoogle Scholar
  14. 14.
    Walter SH, Bertz H, Gerling J. Bilateral optic neuropathy after bone marrow transplantation and cyclosporin A therapy. Graefes Arch Clin Exp Ophthalmol 2000;238(6):472–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Cruz OA, Fogg SG, Roper-Hall G. Pseudotumor cerebri associated with cyclosporine use. Am J Ophthalmol 1996;122(3):436–7.PubMedGoogle Scholar
  16. 16.
    Sung G. Acute treatment of cerebral venous thrombosis. Curr Treat Options Neurol 2002;4(4):319–22.PubMedCrossRefGoogle Scholar
  17. 17.
    al-Tweigeri T, Nabholtz JM, Mackey JR. Ocular toxicity and cancer chemotherapy. A review. Cancer 1996;78(7):1359–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Apaydin C, Gur B, Yakupoglu G, Saka O. Ocular and visual side effects of systemic cyclosporine. Ann Ophthalmol 1992;24(12):465–9.PubMedGoogle Scholar
  19. 19.
    Markman M. Chemotherapy-induced peripheral neuropathy: underreported and underappreciated. Curr Pain Headache Rep 2006;10(4):275–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jade S. Schiffman
    • 1
  • Anitha Raghunath
    • 1
  • Rosa Ana Tang
    • 2
  1. 1.Section of Ophthalmology, Department of Head and Neck SurgeryThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of NeurologyThe University of Texas Health Science Center at HoustonHoustonUSA

Personalised recommendations